	US 12,144,899 B2
	Tetrabenazine transdermal delivery device
Suresh Borsadia, Plainsboro, NJ (US); Kalpana Patel, West Windsor, NJ (US); and Hock S. Tan, East Brunswick, NJ (US)
Assigned to SHINKEI THERAPEUTICS, INC., Princeton, NJ (US)
Appl. No. 17/050,230
Filed by SHINKEI THERAPEUTICS LLC, Princeton, NJ (US)
PCT Filed Apr. 24, 2019, PCT No. PCT/US2019/028900 § 371(c)(1), (2) Date Oct. 23, 2020, PCT Pub. No. WO2019/209940, PCT Pub. Date Oct. 31, 2019.
Claims priority of provisional application 62/662,456, filed on Apr. 25, 2018.
Prior Publication US 2021/0128490 A1, May 6, 2021
Int. Cl. A61K 9/70 (2006.01); A61K 31/4745 (2006.01); A61K 47/14 (2017.01); A61K 47/32 (2006.01); A61K 47/34 (2017.01); A61K 47/38 (2006.01)

CPC A61K 9/7061 (2013.01) [A61K 31/4745 (2013.01); A61K 47/14 (2013.01); A61K 47/32 (2013.01); A61K 47/34 (2013.01); A61K 47/38 (2013.01)]

27 Claims

1. An adhesive composition comprising:

an active ingredient dispersed in a non-reactive acrylate pressure sensitive adhesive, wherein the active ingredient is selected from tetrabenazine, deuterated tetrabenazine, or a combination thereof; and

a crystallization inhibitor which is a polyethylene glycol, polyvinyl acetate, and polyvinylcaprolactame based graft copolymer;

wherein the non-reactive acrylate pressure sensitive adhesive is in an amount of about 50% to about 97% by weight, and wherein the non-reactive acrylate pressure sensitive adhesive does not have functional groups selected from epoxy, —OH, —COOH, and combinations thereof.